Cardio Analysis Services

Richmond Pharmacology's Core ECG Laboratory has worked with numerous clinical units worldwide and participated in 200 clinical trials sponsored by pharmaceutical companies.

Many "normal" healthy volunteers will actually have abnormal ECG's at times or indeed have abnormal ECG's which are missed. These abnormal ECG's may have a big impact on the development of a new chemical entity if the data obtained is not scrutinised properly at an early stage.

As such early signal detection and full follow up by Richmond Pharmacology's cardiology team, lead by Professor Camm, is essential to ensure that the digital ECG data obtained from an early phase trial is analysed and reported appropriately.

Richmond Pharmacology has the capacity to undertake and subsequently analyse a number of cardiological assessments in order to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity. Our offering of an in house clinic trials unit and cardio analysis services all under one roof makes, Richmond Pharmacology the only choice for studies where the cardio profile of a compound may be in question.

Analysis services include rest and exercise ECG analysis, detailed QT analysis, entry criteria validation, and cardiac event classification and Holter provision, analysis and review. Drug development range of services cover phase I-IV ECG safety studies for cardiovascular and non-cardiovascular compounds. Rest, exercise and QT digitized ECG analysis are performed using Richmond's bespoke and integrated MUSE setup.

Our experts

Professor Camm - Professor of Cardiology

Professor Camm's major speciality is cardiac arrhythmias but he is also much involved in clinical cardiac electrophysiology, cardiac pacemakers and risk stratification in post myocardial infarction, heart failure and cardiomyopathy drugs.

Read biography

Dr Jorg Taubel - MD FFPM
(CEO)

Medical practitioner and CEO of Richmond Pharmacology which he co-founded in 2001. He has worked in pharmacology for 24 years and during that time he has conducted more than 400 early phase studies in patient, paediatric and healthy volunteers.

Read biography

Experience

  • Track record of 100% success in conducting QTC studies
  • Many of our QTc studies have been published.

Set-up

  • State of the art methods and equipment
  • Tried and tested processing for ECG adjudication and data analysis

We are

  • Excellence in ECG acquisition allows meaningful ECG analysis
  • Option to include a non-pharmacological method of proving assay sensitivity

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more